Cyclacel Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The analysis of Cyclacel Pharmaceuticals Inc was prepared by All Street Sevva using advanced Cognitive Robots. The Disclosure rating includes seventeen United Nations SDGs including: 'Gender Equality', 'Climate Action' and 'Life below Water'. The SDG rating for Cyclacel Pharmaceuticals Inc represents the company's reporting of the United Nations Sustainable Development Goals.
Cyclacel Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.7; made up of an environmental score of 0.0, social score of 2.7 and governance score of 5.3.
2.7
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1393 | Vaccinex Inc | 2.8 | Medium |
1393 | YSP Southeast Asia Holding Bhd | 2.8 | Medium |
1437 | Cyclacel Pharmaceuticals Inc | 2.7 | Medium |
1437 | CanadaBis Capital Inc | 2.7 | Medium |
1437 | Cannabics Pharmaceuticals Inc | 2.7 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Cyclacel Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Cyclacel Pharmaceuticals Inc disclose current and historical energy intensity?
Does Cyclacel Pharmaceuticals Inc report the average age of the workforce?
Does Cyclacel Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Cyclacel Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Cyclacel Pharmaceuticals Inc disclose cybersecurity risks?
Does Cyclacel Pharmaceuticals Inc offer flexible work?
Does Cyclacel Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Cyclacel Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Cyclacel Pharmaceuticals Inc conduct supply chain audits?
Does Cyclacel Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Cyclacel Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Cyclacel Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Cyclacel Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Cyclacel Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Cyclacel Pharmaceuticals Inc disclose water use targets?
Does Cyclacel Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Cyclacel Pharmaceuticals Inc have a product recall in the last two years?
Does Cyclacel Pharmaceuticals Inc disclose incidents of discrimination?
Does Cyclacel Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Cyclacel Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Cyclacel Pharmaceuticals Inc disclose parental leave metrics?
Does Cyclacel Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Cyclacel Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Cyclacel Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Cyclacel Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Cyclacel Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Cyclacel Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Cyclacel Pharmaceuticals Inc involved in embryonic stem cell research?
Does Cyclacel Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Cyclacel Pharmaceuticals Inc disclose its waste policy?
Does Cyclacel Pharmaceuticals Inc report according to TCFD requirements?
Does Cyclacel Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Cyclacel Pharmaceuticals Inc disclose energy use targets?
Does Cyclacel Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Cyclacel Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Cyclacel Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.